China’s Anti-Monopoly Law (AML) is one of the most consequential pieces of legislation affecting foreign companies operating in or trading with China. First enacted in 2008 and significantly amended in 2022, the AML governs mergers, market dominance, and anti-competitive practices across the Chinese market. For foreign businesses, compliance obligations span cross-border mergers, licensing agreements, distribution arrangements, and day-to-day pricing practices. Understanding the AML is not optional — enforcement has intensified dramatically in the past three years, with record fines levied against both domestic and international firms.
What the Anti-Monopoly Law Covers
The AML, administered by the State Administration for Market Regulation (SAMR), targets three categories of conduct:
- Monopoly agreements: Cartels, price-fixing, market allocation, output restrictions, and coordinated boycotts among competitors (horizontal agreements), as well as resale price maintenance and other vertical agreements between suppliers and distributors.
- Abuse of dominant market position: Unfair pricing, below-cost selling, refusal to deal, exclusive dealing, tying, and applying discriminatory conditions — particularly relevant for platforms and companies with significant market share.
- Concentration of undertakings: Mergers, acquisitions, and joint ventures that meet notification thresholds must be reviewed by SAMR before closing.
The 2022 amendments strengthened enforcement authority, raised maximum fines to as much as 10% of prior-year global revenue for certain violations, and introduced new provisions targeting “concentration by agreement” — an important update for foreign firms structuring joint ventures or strategic alliances in China.
Merger Control: Filing Thresholds and Review Process
Foreign companies planning acquisitions of Chinese businesses — or any deal where both parties have significant China revenue — must evaluate whether pre-merger notification is required. Under the current thresholds (updated via SAMR regulations), a filing is mandatory if:
- The combined worldwide turnover of all parties exceeds RMB 10 billion (approximately USD 1.4 billion), AND
- At least two of the parties each have China turnover exceeding RMB 800 million (approximately USD 110 million).
SAMR reviews transactions in phases: a 30-day Phase 1, an extended 90-day Phase 2, and a further 60-day Phase 3 in complex cases. The clock stops when SAMR requests additional information — a “stop-the-clock” mechanism that can extend practical review timelines significantly. Foreign companies should build at least four to six months into deal timelines for complex cross-border transactions with China nexus.
Failure to notify carries severe penalties: fines up to RMB 5 million for pre-2022 cases, and up to 10% of prior-year China revenue under the amended law. SAMR also has authority to unwind completed transactions that should have been notified.
Monopoly Agreements: What Foreign Businesses Must Avoid
Foreign companies frequently encounter AML risk in distribution and licensing arrangements. The following practices warrant careful legal review:
Resale Price Maintenance (RPM)
Setting minimum resale prices for Chinese distributors — a common practice in premium brand management globally — is presumptively illegal under China’s AML unless the company can rebut the presumption by demonstrating pro-competitive effects. SAMR and courts have taken an increasingly strict stance on RPM since 2013. Foreign brands in cosmetics, electronics, and luxury goods sectors have faced enforcement action on this basis.
Exclusive Dealing and Territorial Restrictions
Prohibiting Chinese distributors from selling competing products, or assigning exclusive geographic territories that foreclose competition, may trigger scrutiny depending on market share. Arrangements where the supplier holds more than 30% market share in the relevant segment face heightened risk.
IP Licensing Agreements
The 2022 amendments explicitly address the intersection of IP rights and AML. Licensing terms that unreasonably restrict a Chinese licensee’s ability to develop competing technology, or that impose grant-back clauses covering improvements, can constitute abuse of IP-based market dominance. Foreign companies licensing technology to Chinese partners should have counsel review AML implications, particularly for patents with significant market power in China.
Abuse of Dominance: Platform Economy Focus
The 2022 amendments introduced specific provisions targeting “platform economy” operators — a direct response to enforcement actions against Alibaba, Meituan, and DiDi. While these provisions primarily target domestic tech giants, foreign platforms or software companies with substantial China market share face the same scrutiny for:
- “Choose one from two” exclusivity demands on business users
- Leveraging data advantages to foreclose competitors
- Using algorithms to implement discriminatory pricing between customer segments
- Self-preferencing — prioritizing the platform operator’s own products in search results or rankings
For Western software companies, SaaS platforms, and enterprise technology providers with China subsidiaries, these provisions require compliance review of customer-facing terms and algorithm-driven pricing systems.
Enforcement Trends: Fines, Dawn Raids, and Settlement
SAMR’s enforcement capacity has grown substantially. The agency operates provincial-level enforcement offices capable of conducting zhusha (dawn raids) with minimal advance notice. Foreign companies with China offices should have protocols in place: employees should know to immediately contact legal counsel, not to destroy or alter documents, and to cooperate professionally while protecting privilege.
Recent notable enforcement actions against foreign companies include investigations into automotive parts manufacturers for price-fixing (resulting in fines exceeding RMB 1.2 billion collectively), pharmaceutical companies for pay-for-delay patent settlements, and infant formula brands for RPM violations. SAMR treats foreign and domestic companies with the same enforcement intensity.
Settlement is available under Chinese AML procedure. Companies under investigation can commit to remedial actions — price adjustments, behavioral changes, or structural remedies — in exchange for reduced or suspended penalties. Engaging proactively with SAMR at early stages, with experienced local counsel, consistently produces better outcomes than confrontational approaches.
AML Compliance Program: What Foreign Companies Should Build
A functional AML compliance program for a foreign company with China operations should include:
1. Market Share Monitoring
Track market share in every product segment where you operate in China. The 30% threshold for presumptive dominance is a key trigger — companies approaching or exceeding this level need heightened compliance protocols for pricing, distribution, and partner agreements.
2. Distribution Agreement Audits
Review all distribution, agency, and licensing contracts with Chinese partners for AML-incompatible clauses. RPM provisions, “most favored nation” pricing clauses, and broad exclusivity arrangements deserve priority review, particularly following the 2022 amendments.
3. M&A Pre-Screening
Before signing any deal with China dimensions, run revenue thresholds against the SAMR notification criteria. Filing late — or failing to file — is a violation regardless of whether the transaction raises competitive concerns. Robust due diligence on Chinese counterparties should include AML exposure as a standard checklist item.
4. Staff Training
Sales, procurement, and business development teams must understand what conversations with competitors are prohibited. Exchanging pricing information at trade fairs or through industry associations — even informally — can constitute evidence of a horizontal monopoly agreement.
5. Dawn Raid Preparedness
Designate a single point of contact for enforcement visits, store a dawn raid protocol in accessible locations, and pre-retain China antitrust counsel with SAMR experience. Data handling obligations under China’s cybersecurity framework intersect with AML compliance during investigations involving digital evidence.
US-China AML Coordination: A Growing Complexity
Cross-border mergers involving US and Chinese parties now routinely require clearance from both the US Department of Justice Antitrust Division and SAMR. The two agencies have occasionally reached divergent conclusions on the same transactions, creating compliance dilemmas for deal teams. The DOJ’s 2023 merger guidelines updated its analytical framework; SAMR’s approach remains more interventionist by global standards, particularly in technology and semiconductor sectors.
Companies managing dual-jurisdiction reviews should retain separate counsel in each jurisdiction, establish information-barrier protocols between US and China legal teams, and prepare for SAMR’s stop-the-clock requests to extend timelines significantly. Understanding China’s investment structure options is equally important, as the chosen vehicle affects both regulatory review timelines and AML obligations.
Practical Takeaways for Foreign Business Leaders
China’s Anti-Monopoly Law has matured into a sophisticated regime with real enforcement teeth. The most immediate priorities for foreign businesses are:
- Audit distribution contracts now — RPM provisions are the most common silent compliance gap for foreign brands.
- Build M&A pre-screens into deal process — the cost of late notification far exceeds the cost of a timely filing.
- Monitor market share annually — dominance thresholds are triggered by actual market conditions, not self-assessment.
- Localize your compliance program — generic global antitrust policies rarely address China-specific AML provisions adequately.
Working in China’s market is a long game. Companies that invest in genuine AML compliance build credibility with regulators and create a foundation for sustainable growth. Those who treat compliance as a checkbox risk enforcement actions that are financially painful and operationally disruptive. For a broader view of the compliance landscape, understanding how investment structures interact with Chinese regulatory frameworks is a natural next step for any serious market entry strategy.